Foghorn Therapeutics Inc - Asset Resilience Ratio
Foghorn Therapeutics Inc (FHTX) has an Asset Resilience Ratio of 39.38% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Foghorn Therapeutics Inc's Asset Resilience Ratio has changed over time. Check FHTX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Foghorn Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see FHTX stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $78.02 Million | 39.38% |
| Total Liquid Assets | $78.02 Million | 39.38% |
Asset Resilience Insights
- Very High Liquidity: Foghorn Therapeutics Inc maintains exceptional liquid asset reserves at 39.38% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Foghorn Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Foghorn Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Foghorn Therapeutics Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Foghorn Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 39.38% | $78.02 Million | $198.10 Million | -26.92pp |
| 2024-12-31 | 66.30% | $188.29 Million | $283.98 Million | +12.54pp |
| 2023-12-31 | 53.76% | $153.72 Million | $285.92 Million | -18.75pp |
| 2022-12-31 | 72.51% | $293.58 Million | $404.88 Million | +62.28pp |
| 2021-12-31 | 10.23% | $53.15 Million | $519.77 Million | -26.15pp |
| 2020-12-31 | 36.38% | $92.97 Million | $255.59 Million | -- |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies f… Read more